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Abstract 
Background/Aims: Uric acid may cause renal damage, whereas adiponectin in some studies 
has been reported to have renoprotective properties. The renoprotective role of adiponectin 
under the influence of hyperuricemia has not been explored. We assessed the cross-sectional 
association between adiponectin, serum uric acid (SUA) and urinary biomarkers of glomerular 
and tubular damage (albumin-creatinine ratio [ACR] and N-acetyl-β-D-glucosaminidase-
creatinine ratio [NAG-CR]) in a large cohort from a general population. Methods: Three urine 
specimens from 7062 persons, participating in the Tromsø Study, were collected.  The adjusted 
associations between adiponectin and SUA as independent variables, and ACR ≥1.13 mg/
mmol (albuminuria) and the upper gender specific 15 percentile of NAG-CR (high NAG-CR) as 
dependent variables, were assessed. Results: Mean (standard deviation) age of the participants 
was 63.5 (9.2) years.  Adiponectin was positively associated with albuminuria and high NAG-
CR. SUA was associated with albuminuria (odds ratio [OR] 1.13; 95% Confidence Interval [CI] 
1.05-1.21 per 59 µmol/L increase), but not with NAG-CR. There were no statistically significant 
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Introduction
Hyperuricemia has in many studies been associated with chronic kidney disease (CKD) 
[1-3]. Uric acid is a strong antioxidant in plasma and at the same time a promoter of oxidative 
and inflammatory processes [4]. Therefore, the role of uric acid in CKD remains controversial; 
a causal relationship has been suggested [5, 6], but not confirmed [7, 8]. Adiponectin is a 
cytokine that is secreted primarily by adipocytes and exerts antidiabetic, anti-inflammatory, 
cardioprotective [9] and renoprotective [10, 11] effects.  However, these effects have not 
been consistently reported, and subgroup differences appear to exist [12-14].
Increased levels of SUA and low adiponectin are frequently observed in the same high-
risk phenotypes, especially in obesity and the metabolic syndrome [15, 16]. The biomarkers 
have shown significant negative correlation [17], but not in all cohorts [18]. Pharmaceutical 
agents such as peroxisome proliferator-activated receptor-ɣ (PPAR ɣ) agonists and xanthine 
oxidase inhibitors [19, 20] have been demonstrated to simultaneously decrease SUA and 
increase adiponectin [21, 22]. Thus, it may be suggested that the two biomarkers share 
some common pathways. Expanded knowledge of a possible interplay between uric acid 
and adiponectin in CKD may have therapeutic potential.
Adiponectin tends to be low in persons with low-grade albuminuria [23-25], and 
increased in more advanced stages of albuminuria and proteinuria [26, 27]. However, 
studies involving persons with low-grade albuminuria have yielded conflicting results [23, 
24, 28], suggesting that the association between adiponectin and urinary albumin excretion 
(UAE) may vary according to underlying risk. In cross-sectional studies, urinary and serum 
adiponectin have been shown to be positively associated with tubular dysfunction in diabetic 
patients [29, 30].
SUA has been demonstrated to be a strong predictor of new-onset micro- and macro-
albuminuria in diabetes [31], and an association between baseline SUA and incident elevations 
in UAE has been found in the general population [32-34]. Since even slightly raised UAE is a 
risk factor for CKD [35], these associations are relevant. Furthermore, SUA correlates with 
the morphological severity of tubulointerstitial lesions in patients with IgA nephropathy 
and normal estimated glomerular filtration rate (eGFR) [36]. In cultured tubular cells, SUA 
causes apoptosis [37], suggesting that SUA is directly involved in tubulointersitial damage. A 
possible association between SUA and urinary N-acetyl-β-D-glucosaminidase (NAG) activity 
was found in a small hypertensive cohort [38]. 
There have so far been no studies relating SUA and adiponectin to glomerular and 
tubular dysfunction in the general population. 
In this cross-sectional study of a large cohort from the Tromsø Study, we aimed to assess 
the separate and joint associations between adiponectin and SUA, and urinary biomarkers 
of glomerular and proximal tubular damage, i.e. UAE measured as albumin-creatinine ratio 
(ACR), and NAG-creatinine ratio (NAG-CR).
Materials and Methods
Study population
The Tromsø Study is a population-based, prospective study of health issues including risk factors, 
CVD and CKD in the municipality of Tromsø, Northern Norway [39]. In the present study, data from subjects 
positively associated with both urinary markers of renal damage. SUA was positively associated 
with albuminuria only. SUA and adiponectin added little beyond traditional cardiovascular risk 
factors to predict renal damage and did not interact in their associations with the urinary 
biomarkers. Longitudinal studies are needed before firm conclusions can be made.
© 2016 The Author(s)
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who attended both visits of the sixth (2007-08) survey (Tromsø 6) are presented. The data collection and 
study population have been described in detail elsewhere [40]. A total of 7307 persons (64% of eligible 
subjects) participated. Among these, 245 persons had one or more missing values of SUA, adiponectin, ACR 
and/or NAG-CR and were therefore excluded from the present study. The Regional Committee for Medical 
and Health Research Ethics and The Norwegian Data Protection Authority approved the study, and all 
participants gave their informed, written consent.  
Measurements
Self-reported information about smoking habits, alcohol intake, leisure physical activity, current 
medication (yes/no/earlier, and a list of all drugs currently used regularly), presence of diabetes and 
CVD was collected through a questionnaire that was checked by health personnel at the study site. The 
questionnaires and variables are available at the Tromsø Study web site (https://uit.no/Content/401052/
Questionnaire_T6_1.pdf). Tobacco use was classified as current smokers or not (all others). Alcohol intake 
was categorised according to frequency of alcohol intake (once a month or less often, twice a month to once 
a week, 2-3 times a week, or more frequently). Leisure physical activity was dichotomised as active (≥1 
hour of physical activity with prominent perspiration or breathlessness per week), or inactive (all others). 
Verified information about previous myocardial infarction and/or ischaemic stroke was obtained from the 
Tromsø Study Cardiovascular Disease Registry [41]. Blood pressure was recorded in triplets, and the mean 
of the two last readings was used in the analyses. Hypertension was defined as systolic blood pressure ≥140 
mm Hg, diastolic blood pressure ≥90 mm Hg and/or current use of blood pressure lowering medication. 
Height, weight and waist circumference were measured, and body mass index (BMI) was calculated [40].
First-void morning urine samples from three consecutive days were collected. Albumin and creatinine 
were measured in unfrozen urine within 20 hours after collection using an ABX PENTRA autoanalyser 
(Horiba ABX) and kits from ABX Diagnostics (Montpellier, France). The rest of the urine was stored at 
-20°C. In 2014-15, NAG was measured by a colorimetric method (with 3-cresolsulfonphthaleyn-N-β-D-
glucosaminide, Boehringer Mannheim, Germany) in thawed morning urine samples. The concentration of 
each urinary biomarker was divided by the creatinine concentration of the same specimen, and the median 
values of ACR and NAG-CR from the three specimens were used in the analyses. In order to achieve values 
of similar magnitude for both variables, mg/mmol was chosen as the unit for ACR, whereas NAG-CR was 
reported in U/g.  ACR was dichotomised into “albuminuria”, i.e. ACR ≥1.13 mg/mmol, or not albuminuria. 
The cut-off corresponds to the suggested lower limit for “high normal” ACR in the 2012 CKD definition from 
KDIGO [42]. There is no generally suggested cut-off for NAG-CR, and in order to classify approximately the 
same number of participants in the “high NAG-CR” group as in the “albuminuria” group, we applied the 
gender-specific upper 15 percentile to define the group with high NAG-CR.
A non-fasting blood sample was obtained. SUA was measured by photometry with COBAS® instruments 
(Roche diagnostics, Switzerland) using an enzymatic colorimetric test, the uricase/PAP method. In 2012, 
adiponectin was measured in stored serum (-70°C). An ELISA method (DY1065 kit from R&D Systems, 
Inc., Minneapolis, MN) was used. All samples were analysed in duplicate, and the mean value was used. 
Two control samples were run for each assay to monitor between-assay variation, and the inter-assay 
coefficients of variation were found to be 7.89% and 7.74% respectively. Serum creatinine was analysed 
using an enzymatic method that has been standardised against isotope dilution mass spectroscopy (CREA 
Plus, Roche Diagnostics, GmbH, Mannheim, Germany). Cystatin C was measured with particle-enhanced 
turbidimetric immunoassay (Gentian AS, Moss, Norway) using a Modular E analyzer (Roche Diagnostics, 
Mannheim, Germany). eGFR was calculated according to the CKD-EPI creatinine equation (eGFRcre) [43] 
and the CKD-EPI creatinine-cystatin C equation (eGFRcrecys) [44]. Serum lipids, glucose and glycosylated 
haemoglobin A1c (HbA1c) were analysed as previously described[40] [45]. Prevalent diabetes was defined 
as self-reported diabetes mellitus, self-reported use of antidiabetic medication, HbA1c ≥6.5% or non-fasting 
plasma glucose >10.0 mmol/L. 
Statistical Analysis
Continuous data are presented as mean (±standard deviation [±SD]) or median (interquartile range) 
as appropriate. We checked the bivariate correlations between SUA, adiponectin, eGFRcre, eGFRcrecys, ACR and 
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regression analyses were used to assess the cross-sectional, multivariable adjusted associations between 
adiponectin and SUA as continuous variables, and the dichotomised urinary biomarkers, albuminuria and 
NAG-CR. Covariates were added block wise, and four models were fitted for each dependent variable. All 
models were age and gender adjusted. In Model 1 and 2, adiponectin and SUA, respectively, were entered as 
the only additional covariate. In Model 3, both SUA, adiponectin and eGFRcrecys, were included. Traditional 
cardiovascular risk factors and current medication use (systolic blood pressure, waist circumference, 
cholesterol, triglycerides, HbA1c, current smoking, physical activity, alcohol use, prevalent diabetes, previous 
myocardial infarction and/or ischaemic stroke, current use of diuretics, blockers of the renin-angiotensin 
system, lipid lowering drugs, antiplatelet drugs and allopurinol) were added as covariates in Model 4. Non-
linearity was tested for using fractional polynomial models.  By applying the same regression models, we 
repeated the analyses in the following subgroups: subjects with hypertension (n=4422), diabetes (n=569) 
and prevalent CVD (previous myocardial infarction and/or ischaemic stroke; n=559).
We applied c-statistics to estimate the area under receiver-operating-characteristic (ROC) curve (AUC) 
of a basal model (Model A) that included all the mentioned cardiovascular risk factors as covariates. AUC 
was also calculated when SUA (Model B) and finally adiponectin (Model C) were added. We did this in order 
to assess the additional predictive value of SUA and adiponectin for albuminuria and high NAG-CR. The 
equality of the AUC of the ROC curves in Model B and C compared to Model A was tested. 
SUA was dichotomised into hyperuricemia and “normal” SUA according to the gender specific cut-
offs applied in the NHANES III and 2007-2008  studies (SUA ≥339 µmol/L for women and ≥416 µmol/L 
for men) [46]. Reference values for adiponectin vary between methods of analysis, and no generally 
accepted cut-off suggesting a pathologically low value exists. We chose to dichotomise adiponectin into 
values below or above the lower gender-specific 15 percentile to ensure approximately the same number 
of individuals in the low-adiponectin group as in the hyperuricemia group. The cohort was classified into 
four groups according to whether SUA was unfavourable (hyperuricemia) or “normal”, and correspondingly 
whether adiponectin was unfavourable (“low”) or “normal”. The group with “normal” SUA and adiponectin 
served as reference.  We used ANCOVA to calculate the adjusted mean log-transformed values of the two 
urinary biomarkers within the four groups, adjusting for the same covariates used in Model 4 of the logistic 
regression analyses. Mean log-values of ACR and NAG-CR were back-transformed to obtain the geometric 
mean of each biomarker in each of the four groups, and 95% confidence intervals (CI) for the geometric 
mean are presented. Analyses were done using IBM SPSS Statistics software version 22 (IBM Corporation, 
Armonk, New York) and StataMP 14 (StataCorp LP, Texas).
Results 
Study Population
The final cohort included 7062 participants (3030 men; 4032 women). Cardiovascular 
risk factors were compared between the 245 subjects who attended the second visit of 
Tromsø 6, but were excluded due to missing values for at least one biomarker of interest, 
and the 7062 participants. No significant differences were found (data not shown).
Cohort characteristics
The cohort characteristics are presented in Table 1. Mean age was 63.5 (±9.2) years, and 
mean BMI was in the overweight, but not obese, category. A third of the cohort was on an-
tihypertensive treatment, and 8.1% had diabetes. Among the 569 participants with diabetes, 
333 received pharmacological treatment; 209 were using blood sugar lowering tablets (sulf-
onylurea agents and/ or metformin), 37 used insulin and 87 were treated with a combination 
of insulin and other blood sugar lowering drugs. Only 343 individuals (4.9%) had ACR in the 
A2 range or above according to the 2012 KDIGO CKD classification (ACR ≥3.39 mg/mmol; 
also called micro- or macroalbuminuria) whereas 514 men (17.0%) and 545 women (13.5%) 
had ACR above the “high normal” cut-off (≥1.13 mg/mmol). In spite of the relatively high age, 
only 351 participants (5.0%) had eGFRcrecys <60 ml/min/1.73 m2. Hyperuricemia was found 
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had a stronger negative correlation to all the urinary biomarkers than eGFRcre. Interestingly, 
the absolute value of the correlations between SUA and both GFR estimates were <0.30 and 
thus considered weak. Both adiponectin and SUA were positively correlated to age (r=0.20, 
and r=0.12, respectively; P<0.001).
Multivariable associations between SUA, adiponectin and the urinary biomarkers
There was no non-linear association between adiponectin and the urinary biomarkers. 
A weak association was found between SUA to the third degree and ACR. A fractional 
polynomial plot suggested that this association was valid only at extreme values of SUA, and 
when the 15 observations of SUA ≥600 µmol/L were omitted from the analyses, the non-
linear association disappeared. 
Table 1. Cohort characteristics, n=7062. The Tromsø Study: Tromsø 6a SUA lowering drug 
other than allopu-
rinol (probenecid). 
This drug class has 
therefore not been 
accounted for in the 
analyses. The ran-
ge of adiponectin 
values in the cohort 
were 0.30-13.28 µg/
mL in men and 0.20-




lations between the 
urinary biomarkers, 
SUA, adiponectin, 
eGFRcre and eGFRcrecys 
were all highly sig-
nificant; the r valu-
es are presented in 





adiponectin and the 
urinary biomarkers 
were significant, 
they were weak 
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was also only wea-
kly correlated with 
ACR and NAG-CR, 
and the unadjusted 
correlation between 
SUA and NAG was 
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The adjusted odds ratios (ORs) for albuminuria (ACR ≥1.13 mg/mmol) and NAG-CR 
(upper 15 percentile) by adiponectin and SUA as predictor variables are shown in Table 3. 
In age and gender adjusted models, higher adiponectin was significantly associated with 
higher NAG-CR, but not with albuminuria, whereas SUA was associated with albuminuria 
only. When both adiponectin and SUA were entered into the same model and adjusted 
for age, gender and eGFRcrecys, the estimates were not substantially changed. With further 
adjustment for cardiovascular risk factors and medication use, the association between 
SUA and albuminuria was attenuated, whereas the associations between adiponectin and 
both urinary biomarkers were strengthened. In the fully adjusted model (Model 4), 1 µg/mL 
increase in adiponectin was associated with a 11% and 9% increased risk of albuminuria 
and high NAG-CR, respectively. There was no statistically significant interaction between 
SUA and adiponectin for the association with ACR and NAG-CR (P=0.36 and 0.56). There 
was a significant interaction between SUA and gender for the prediction of ACR (P=0.002). 
In gender stratified analyses SUA was a significant predictor of ACR in men only (OR per 59 
Table 2. Spearman's correlations between renal biomarkers.  The Tromsø Study: Tromsø 6
Table 3. Odds ratios (OR) for having albuminuria (urinary albumin/creatinine ratio (ACR) ≥1.13 mg/mmol 
or N-acetyl-β-D-glucosaminidase/creatinine ratio (NAG/crea) in the upper gender-specific 15 percentile. 
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µmol/L increase was 1.18; 95% CI 1.07-1.30 in men and 1.09; 95% CI 0.98-1.21 in women).
eGFRcrecys was negatively associated with albuminuria and NAG-CR in the upper 15 
percentile. 
The associations between adiponectin and SUA and the urinary biomarkers were not 
substantially different in subgroup analyses that included hypertensive subjects (n=4422) 
or subjects with prevalent CVD (n=559). However, when the same models were run in the 
subgroup with diabetes (n=569), neither adiponectin nor SUA was associated with any of the 
urinary biomarkers (data not shown).
AUC of ROC curves
The AUC of ROC curves for predicting albuminuria and high NAG-CR did not increase 
significantly when SUA was added to the baseline model of covariates.  Further addition of 
adiponectin slightly, and significantly, increased the predictive value for both biomarkers 
(Table 4). 
Adjusted values for the urinary biomarkers
Multivariable adjusted geometric means of both urinary biomarkers for the groups 
based on “normal” or unfavourable SUA and adiponectin, are displayed in Table 5. Although 
the between-group differences were reduced with multivariable adjustment, ACR remained 
higher in the group with high SUA and “normal” adiponectin compared to the reference group 
Table 4. Area under the ROC curve (AUC) for the prediction of increased albumin creatinine ratio 
(ACR) ≥1.13 mg/mmol and the upper 15 percentile of N-acetyl-β-D-glucosaminidase creatinine 
ratio (NAG-CR), using different prediction models. The Tromsø Study: Tromsø 6
Table 5. Urinary biomarkers according to classification of serum adiponectin and uric acid (SUA). 
Adiponectin is classified as low (lower gender specific 15%) or normal (upper gender specific 85%); SUA is 
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with “normal” SUA and adiponectin (P=0.04). ACR in the two remaining groups did not differ 
significantly from the reference group. The geometric mean of NAG-CR was lower in the 
two groups with low adiponectin compared to reference (P=0.03 and P=0.002, respectively), 
whereas NAG-CR in the group with unfavourable SUA only was not significantly different 
from the reference group. 
Discussion
In this large cohort from the general population, we found that although SUA 
and adiponectin were correlated, they were differentially associated with two urinary 
biomarkers of glomerular and tubular dysfunction, respectively. Firstly, SUA was positively 
associated with albuminuria, but not related to high NAG-CR. Secondly, in this overall low-
risk cohort with a normal mean eGFR and low-grade albuminuria, we expected to find a 
negative association between adiponectin and the urinary biomarkers. To the contrary, an 
independent and positive association was found. The associations were essentially the same 
in subgroup analyses of hypertensive subjects and participants with prevalent CVD, but not 
in the diabetic subgroup. Thirdly, there were no statistically significant interactions between 
SUA and adiponectin for the associations with any of the urinary biomarkers. Finally, 
although c-statistics revealed that SUA and adiponectin added significantly to the prediction 
of albuminuria and high NAG-CR beyond traditional cardiovascular risk factors and eGFR, 
the contribution was small.
Although low adiponectin repeatedly has been demonstrated to be associated with 
low-grade albuminuria [23, 24, 47], this finding has not been consistent [28]. However, to 
our knowledge, a positive association between adiponectin and low-grade UAE in a low-
risk cohort has not previously been reported. The similar association between adiponectin 
and both urinary biomarkers strengthens the assumption that the result was not a spurious 
finding and a type I error. It has been suggested that the elevated serum adiponectin 
observed in patients with advanced stages of CKD [48, 49] is a compensatory response to 
glomerular damage or adiponectin resistance [50] or secondary to reduced clearance [51]. 
In our low-risk cohort, we did not expect these mechanisms to be important, but we cannot 
exclude their involvement. Moreover, although age was adjusted for, a phenomenon related 
to aging is another possible explanation for the positive association observed in this cohort 
of relatively old individuals; adiponectin increases with age [52] and is associated with 
adverse outcome in the elderly [53].
NAG is a protein that is not filtered through the glomerulus, and all NAG present in 
the urine has been secreted by proximal tubular cells. Therefore, NAG is considered a 
marker of tubular dysfunction or damage [54, 55]. NAG has been demonstrated to predict 
vascular disease in patients with diabetes [56], and we recently published that NAG-CR was 
independently, though weakly, associated with CVD and all-cause mortality in the general 
population [41]. We also showed that increasing NAG-CR was related to a more adverse 
cardiovascular risk profile. Despite these relationships, the present study does not support a 
connection between SUA and early proximal tubular damage in the general population. Based 
on the lack of association between SUA and NAG-CR, we suggest that the positive association 
between SUA and ACR in this low-risk populations is a reflection of generalised endothelial 
dysfunction [57] or slight glomerular damage, rather than low-grade tubular damage. 
Our hypothesis that there may be an interaction between SUA and adiponectin in their 
association with low-grade kidney damage was not supported by the present results, neither 
in the entire cohort nor among hypertensive subjects and participants with prevalent CVD. 
However, it should be noted that the ranges of important laboratory measurements, especially 
eGFR, ACR, and adiponectin, were relatively narrow. Therefore, extrapolation of the results to 
patients with more extreme values should not be done. In a recently published, large cohort 
























   
   
   
   
   
   





















 Kidney Blood Press Res 2016;41:623-634
DOI: 10.1159/000447931
Published online: September 14, 2016
© 2016 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 631
Solbu et al.: Adiponectin, Uric Acid and Markers of Renal Damage
References
1 Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, Kestenbaum B, Carney JK, Fried LF: 
Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007;50:239-247.
2 Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S: Significance of hyperuricemia on the early 
detection of renal failure in a cohort of screened subjects. Hypertens Res 2001;24:691-697.
analysis, was strongly associated with CKD, defined as eGFR <60 mL/min/1.73 m2, as well as 
with SUA [58]. Adiponectin was not measured in this study, but low adiponectin and visceral 
fat area has previously been shown to be highly intercorrelated [16]. Thus, our findings do 
not exclude the possibility of an interaction in subgroups, and SUA and adiponectin may act 
synergistically with regard to more advanced stages of CKD [58-60], and in subjects with 
less favourable values of SUA, adiponectin and the urinary biomarkers. This matter is of 
relevance since pharmaceutical agents such as PPAR γ agonists [21, 22] and some blockers 
of the renin-angiotensin system [61, 62] are known to simultaneously decrease SUA and 
increase adiponectin, and thus these biomarkers may share common pathways. Therefore, 
this issue should be addressed further through longitudinal studies. 
The main strengths of the present study were the large cohort size, high attendance 
rate, large number of covariates and the use of three urine samples to reduce the day-to-
day variation of protein excretion. Albumin was measured in fresh urine. However, NAG 
was measured after prolonged storage of the urine, which may have affected the results. 
The cohort consisted almost exclusively of middle-aged to old Caucasian individuals, which 
restricts the generalisability. The cross-sectional design of the study was its main limitation, 
and the associations should be reassessed in cohorts with short- and long-term follow-
up, and related to hard endpoints. Furthermore, there is a complex interplay between uric 
acid, adiponectin and other cytokines, including monocyte chemotactic protein-1 [60], and 
interleukins, and these biomarkers would have added valuable information to the study. 
However, for logistic and financial reasons, only adiponectin was analysed in this large 
cohort, which is a limitation.
Conclusion
In a large cohort of middle-aged to elderly persons from the general population, we 
found no statistically significant interaction between adiponectin and SUA in their association 
with two urinary biomarkers of kidney damage, and their individual and joint contribution 
to the prediction of the biomarkers was small. Unexpectedly, adiponectin was positively 
associated with all the urinary biomarkers, and SUA was positively associated with ACR only. 
The relationships between promoting and protective factors and low-grade kidney damage 






























   
   
   
   
   
   





















 Kidney Blood Press Res 2016;41:623-634
DOI: 10.1159/000447931
Published online: September 14, 2016
© 2016 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 632
Solbu et al.: Adiponectin, Uric Acid and Markers of Renal Damage
3 Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S: Significance of hyperuricemia as a risk factor for 
developing esrd in a screened cohort. Am J Kidney Dis 2004;44:642-650.
4 Kang DH, Ha SK: Uric acid puzzle: Dual role as anti-oxidantand pro-oxidant. Electrolyte Blood Press 
2014;12:1-6.
5 Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ: A role for uric 
acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888-2897.
6 Uedono H, Tsuda A, Ishimura E, Yasumoto M, Ichii M, Ochi A, Ohno Y, Nakatani S, Mori K, Uchida J, Nakatani 
T, Inaba M: Relationship between serum uric acid levels and intrarenal hemodynamic parameters. Kidney 
Blood Press Res 2015;40:315-322.
7 Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P: Is hyperuricemia an independent risk factor for new-onset chronic 
kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC 
Nephrology 2014;15:122.
8 Guessous I, Ponte B, Marques-Vidal P, Paccaud F, Gaspoz JM, Burnier M, Waeber G, Vollenweider P, Bochud 
M: Clinical and biological determinants of kidney outcomes in a population-based cohort study. Kidney 
Blood Press Res 2014;39:74-85.
9 Nigro E, Scudiero O, Monaco ML, Palmieri A, Mazzarella G, Costagliola C, Bianco A, Daniele A: New insight 
into adiponectin role in obesity and obesity-related diseases. Biomed Res Int 2014;2014:658913.
10 Nakamaki S, Satoh H, Kudoh A, Hayashi Y, Hirai H, Watanabe T: Adiponectin reduces proteinuria in 
streptozotocin-induced diabetic wistar rats. Exp Biol Med (Maywood) 2011;236:614-620.
11 Sweiss N, Sharma K: Adiponectin effects on the kidney. Best Pract Res Clin Endocrinol Metab 2014;28:71-
79.
12 Onat A, Hergenc G, Dursunoglu D, Kucukdurmaz Z, Bulur S, Can G: Relatively high levels of serum 
adiponectin in obese women, a potential indicator of anti-inflammatory dysfunction: Relation to sex 
hormone-binding globulin. Int J Biol Sci 2008;4:208-214.
13 Onat A, Hergenc G, Can G, Kucukdurmaz Z: Serum adiponectin confers little protection against diabetes and 
hypertension in turkish men. Obesity 2009;17:564-570.
14 Laughlin GA, Barrett-Connor E, May S, Langenberg C: Association of adiponectin with coronary heart 
disease and mortality: The rancho bernardo study. Am J Epidemiol 2007;165:164-174.
15 Mascarenhas-Melo F, Sereno J, Teixeira-Lemos E, Marado D, Palavra F, Pinto R, Rocha-Pereira P, Teixeira F, 
Reis F: Implication of low hdl-c levels in patients with average ldl-c levels: A focus on oxidized ldl, large hdl 
subpopulation, and adiponectin. Mediators Inflamm 2013;2013:612038.
16 Takahara M, Katakami N, Kaneto H, Noguchi M, Shimomura I: Contribution of visceral fat accumulation 
and adiponectin to the clustering of metabolic abnormalities in a japanese population. J Atheroscl Thromb 
2014;21:543-553.
17 Park CS, Ihm S-H, Park H-J, Shin W-S, Kim P-J, Chang K, Kim H-Y, Youn H-J, Chung W-S, Seung KB, Kim J-H: 
Relationship between plasma adiponectin, retinol-binding protein 4 and uric acid in hypertensive patients 
with metabolic syndrome. Korean Circ J 2011;41:198-202.
18 Onat A, Can G, Ornek E, Altay S, Yuksel M, Ademoglu E: Elevated serum uric acid in nondiabetic people 
mark pro-inflammatory state and hdl dysfunction and independently predicts coronary disease. Clin 
Rheumatol 2013;32:1767-1775.
19 Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, Yamamoto T, Hara S: Effects of topiroxostat 
on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease 
patients with or without gout. Clin Exp Nephrol 2014;18:876-884.
20 Nishizawa T, Taniura T, Nomura S: Effects of febuxostat on platelet-derived microparticles and adiponectin 
in patients with hyperuricema. Blood Coagul Fibrinolysis 2015;26:887-892.
21 Halvorsen B, Heggen E, Ueland T, Smith C, Sandberg WJ, Damås JK, Otterdal K, Tonstad S, Aukrust P: 
Treatment with the pparγ agonist rosiglitazone downregulates interleukin-1 receptor antagonist in 
individuals with metabolic syndrome. Eur J Endocrinol 2010;162:267-273.
22 Rutkowski JM, Wang ZV, Park AS, Zhang J, Zhang D, Hu MC, Moe OW, Susztak K, Scherer PE: Adiponectin 
promotes functional recovery after podocyte ablation. J Am Soc Nephrol 2013;24:268-282.
23 Barlovic DP, Zaletel J, Prezelj J: Association between adiponectin and low-grade albuminuria is bmi-
























   
   
   
   
   
   





















 Kidney Blood Press Res 2016;41:623-634
DOI: 10.1159/000447931
Published online: September 14, 2016
© 2016 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 633
Solbu et al.: Adiponectin, Uric Acid and Markers of Renal Damage
24 Tsioufis C, Dimitriadis K, Chatzis D, Vasiliadou C, Tousoulis D, Papademetriou V, Toutouzas P, Stefanadis 
C, Kallikazaros I: Relation of microalbuminuria to adiponectin and augmented c-reactive protein levels in 
men with essential hypertension. Am J Cardiol 2005;96:946-951.
25 Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, Ouedraogo R, Hough K, McCue P, Chan L, 
Falkner B, Goldstein BJ: Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 
2008;118:1645-1656.
26 Zoccali C, Mallamaci F, Panuccio V, Tripepi G, Cutrupi S, Parlongo S, Catalano F, Tanaka S, Ouchi N, Kihara S, 
Funahashi T, Matsuzawa Y: Adiponectin is markedly increased in patients with nephrotic syndrome and is 
related to metabolic risk factors. Kidney Int Suppl 2003:S98-102.
27 Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D: Adiponectin in chronic kidney 
disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 
2005;20:129-134.
28 Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, 
Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura 
T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel, adipose-specific protein, 
adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-1599.
29 Panduru NM, Saraheimo M, Forsblom C, Thorn LM, Gordin D, Wadén J, Tolonen N, Bierhaus A, Humpert PM, 
Groop P-H: Urinary adiponectin is an independent predictor of progression to end-stage renal disease in 
patients with type 1 diabetes and diabetic nephropathy. Diabetes Care 2015;38:883-890.
30 Fujita H, Morii T, Koshimura J, Ishikawa M, Kato M, Miura T, Sasaki H, Narita T, Ito S, Kakei M: Possible 
relationship between adiponectin and renal tubular injury in diabetic nephropathy. Endocr J 2006;53:745-
752.
31 Jalal DI, Rivard CJ, Johnson RJ, Maahs DM, McFann K, Rewers M, Snell-Bergeon JK: Serum uric acid levels 
predict the development of albuminuria over 6 years in patients with type 1 diabetes: Findings from the 
coronary artery calcification in type 1 diabetes study. Nephrol Dial Transplant 2010;25:1865-1869.
32 Chang HY, Lee PH, Lei CC, Tung CW, Hsu YC, Huang TJ, Lu LC, Lin CL: Hyperuricemia is an independent risk 
factor for new onset micro-albuminuria in a middle-aged and elderly population: A prospective cohort 
study in taiwan. PLoSOne 2013;8:e61450.
33 Liao L-N, Liu C-S, Li C-I, Lin W-Y, Lin C-H, Li T-C, Lin C-C: Three-year incidence of elevated albuminuria and 
associated factors in a population-based cohort: The taichung community health study. Eur J Prev Cardiol 
2015;22:788-797.
34 Storhaug HM, Toft I, Norvik JV, Jenssen T, Eriksen BO, Melsom T, Lochen ML, Solbu MD: Uric acid is 
associated with microalbuminuria and decreased glomerular filtration rate in the general population 
during 7 and 13 years of follow-up: The tromso study. BMC Nephrol 2015;16:210.
35 Gansevoort RT, Matsushita K, van d, V, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J: Lower 
estimated gfr and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-
analysis of general and high-risk population cohorts. Kidney Int 2011;80:93-104.
36 Zhou J, Chen Y, Liu Y, Shi S, Li X, Wang S, Zhang H: Plasma uric acid level indicates tubular interstitial 
leisions at early stage of iga nephropathy. BMC Nephrol 2014;15:11.
37 Verzola D, Ratto E, Villaggio B, Parodi EL, Pontremoli R, Garibotto G, Viazzi F: Uric acid promotes apoptosis 
in human proximal tubule cells by oxidative stress and the activation of nadph oxidase nox 4. PLoS One 
2014;9:e115210.
38 Tylicki L, Manitius J, Lysiak-Szydlowska W, Rutkowski B: Tubular injury: The first symptom of hypertensive 
kidney involvement? Med Sci Monit 2003;9:CR135-CR141.
39 Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njølstad I: Cohort profile: The tromsø study. Int J 
Epidemiol 2012;41:961-967.
40 Eggen AE, Mathiesen EB, Wilsgaard T, Jacobsen BK, Njølstad I: The sixth survey of the tromsø study 
(tromsø 6) in 2007–08: Collaborative research in the interface between clinical medicine and 
epidemiology: Study objectives, design, data collection procedures, and attendance in a multipurpose 
population-based health survey. Scand J Public Health 2013;41:65-80.
41 Solbu MD, Toft I, Løchen M-L, Mathiesen EB, Eriksen BO, Melsom T, Njølstad I, Wilsgaard T, Jenssen TG: 
N-acetyl-β-d-glucosaminidase does not enhance prediction of cardiovascular or all-cause mortality by 
























   
   
   
   
   
   





















 Kidney Blood Press Res 2016;41:623-634
DOI: 10.1159/000447931
Published online: September 14, 2016
© 2016 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 634
Solbu et al.: Adiponectin, Uric Acid and Markers of Renal Damage
42 Levey AS, Coresh J: Chronic kidney disease. Lancet 2012;379:165-180.
43 Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, III, Feldman HI, Kusek JW, Eggers P, Van LF, Greene T, 
Coresh J: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612.
44 Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van LF, Zhang YL, 
Coresh J, Levey AS: Estimating glomerular filtration rate from serum creatinine and cystatin c. N Engl J Med 
2012;367:20-29.
45 Bertelsen G, Peto T, Lindekleiv H, Schirmer H, Solbu MD, Toft I, Sjolie AK, Njolstad I: Sex differences in 
risk factors for retinopathy in non-diabetic men and women: The tromso eye study. Acta Ophthalmol 
2014;92:316-322.
46 Zhu Y, Pandya BJ, Choi HK: Prevalence of gout and hyperuricemia in the us general population: The national 
health and nutrition examination survey 2007–2008. Arthritis Rheum 2011;63:3136-3141.
47 Meyvis K, Verrijken A, Wouters K, Van Gaal L: Plasma adiponectin level is inversely correlated with 
albuminuria in overweight and obese nondiabetic individuals. Metabolism 2013;62:1570-1576.
48 Doumatey AP, Zhou J, Huang H, Adeleye J, Balogun W, Fasanmade O, Johnson T, Oli J, Okafor G, Amoah 
A, Eghan B, Agyenim-Boateng K, Acheampong J, Adebamowo C, Adeyemo A, Rotimi CN: Circulating 
adiponectin is associated with renal function independent of age and serum lipids in west africans. Int J 
Nephrol 2012;2012:730920.
49 Lim CC, Teo BW, Tai ES, Lim SC, Chan CM, Sethi S, Wong TY, Sabanayagam C: Elevated serum leptin, 
adiponectin and leptin to adiponectin ratio is associated with chronic kidney disease in asian adults. PLoS 
ONE 2015;10:e0122009.
50 Martinez Cantarin MP, Waldman SA, Doria C, Frank AM, Maley WR, Ramirez CB, Keith SW, Falkner B: The 
adipose tissue production of adiponectin is increased in end-stage renal disease. Kidney Int 2013;83:487-
494.
51 Komura N, Kihara S, Sonoda M, Maeda N, Tochino Y, Funahashi T, Shimomura I: Increment and impairment 
of adiponectin in renal failure. Cardiovasc Res 2010;86:471-477.
52 Obata Y, Yamada Y, Takahi Y, Baden MY, Saisho K, Tamba S, Yamamoto K, Umeda M, Furubayashi A, 
Matsuzawa Y: Relationship between serum adiponectin levels and age in healthy subjects and patients with 
type 2 diabetes. Clin Endocrinol 2013;79:204-210.
53 Macheret F, Bartz TM, Djousse L, Ix JH, Mukamal KJ, Zieman SJ, Siscovick DS, Tracy RP, Heckbert SR, Psaty 
BM, Kizer JR: Higher circulating adiponectin levels are associated with increased risk of atrial fibrillation in 
older adults. Heart 2015;101:1368-1374.
54 Bosomworth MP, Aparicio SR, Hay AW: Urine n-acetyl-beta-d-glucosaminidase--a marker of tubular 
damage? Nephrol Dial Transplant 1999;14:620-626.
55 Siew ED, Ware LB, Ikizler TA: Biological markers of acute kidney injury. J Am Soc Nephrol 2011;22:810-
820.
56 Weitgasser R, Schnoell F, Gappmayer B, Kartnig I: Prospective evaluation of urinary n-acetyl-beta-d-
glucosaminidase with respect to macrovascular disease in elderly type 2 diabetic patients. Diabetes Care 
1999;22:1882-1886.
57 Stehouwer CD, Smulders YM: Microalbuminuria and risk for cardiovascular disease: Analysis of potential 
mechanisms. J Am Soc Nephrol 2006;17:2106-2111.
58 Kang SH, Cho KH, Park JW, Yoon KW, Do JY: Association of visceral fat area with chronic kidney disease and 
metabolic syndrome risk in the general population: Analysis using multi-frequency bioimpedance. Kidney 
Blood Press Res 2015;40:223-230.
59 DeMarco VG, Aroor AR, Sowers JR: The pathophysiology of hypertension in patients with obesity. Nat Rev 
Endocrinol 2014;10:364-376.
60 Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C, Johnson RJ, Sautin YY: Hyperuricemia as a 
mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the 
metabolic syndrome. Diabetes 2011;60:1258-1269.
61 Jian D-Y, Chao Y-W, Ting C-H, Huang S-W, Chang C-F, Juan C-C, Chen J-Y: Losartan ameliorates renal injury, 
hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats. Eur J Pharmacol 2013;709:85-92.
62 Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De FU, Fyhrquist F, Ibsen H, Kristianson 
K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Dahlof B: The 
























   
   
   
   
   
   
   
  
12
9.
24
2.
14
2.
12
3 
- 
2/
2/
20
17
 2
:1
8:
17
 P
M
